NCT01742663已完成1 期
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 435
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study is to compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis.
Both the test and reference formulations will also be compared to a placebo formulation to test for superiority.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form.
- •Immunocompetent male or non-pregnant, non-lactating female at least 18 years of age.
- •Diagnosis of AK with at least 5 and no more than 10 clinically typical, visable, discrete, nonhyperkeratotic, nonhypertrophic AK lesions each at least 4 mm in diameter on the face and/or bald scalp contained within a 25 cm2 treatment area.
- •Women either must be 1 year post-menopausal, surgically sterile, or if they are of child-bearing potential they must have been using systemic birth control, IUD or Norplant for at least 28 days prior to treatment start, or used barrier methods consistently at least 14 days before study gel administration, had a normal menstrual cycle for the month prior to the start of treatment, have a negative urine pregnancy test result upon entry into the study and agree to use a medically accepted form of birth control throughout the study period.
- •Free from any systemic or dermatologic disorder that, in the opinion of the investigator, will interfere with the study results or increase the risks of AEs.
- •Any skin type or race, providing the skin pigmentation will allow discernment of erythema.
- •Willingness and capability to cooperate to the extent and degree required by the protocol.
排除标准
- •Active gastrointestinal ulceration or bleeding.
- •Current or history of severe renal or hepatic impairment.
- •Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema, psoriasis, rosacea, sunburn or other possible confounding skin conditions on the face or bald scalp.
- •Use within six months prior to randomization of oral isotretinoin.
- •Use within six months prior to baseline on the face or bald scalp of chemical peel, dermabrasion, laser abrasion, PUVA therapy or UVB therapy.
- •Use within one month prior to baseline on the face or bald scalp of cryodestruction or chemodestruction, curettage, photodynamic therapy, surgical excision, topical 5-fluorouracil, topical corticosteroids, topical diclofenac, topical Imiquimod, topical retinoids or other treatments for actinic keratosis including glycolic acids or over-the-counter products containing retinol, alpha or beta hydroxy acids.
- •Use within one month prior to baseline of immunomodulators or immunosuppressive therapies, interferon, systemic corticosteroids or cytotoxic drugs.
- •Known allergies to diclofenac sodium, benzyl alcohol, polyethylene glycol monomethyl ether 359, hyaluronate sodium or any excipients in the test or reference gels.
- •Receiving 5-Fluorouracil or other systemic cancer chemotherapy within 6 months prior to study entry.
- •Any condition, medical, psychological or social, that, in the investigator's opinion, would interfere with participation in the study.
- •Women who are pregnant or planning pregnancy or lactating during the study.
- •Participation in any investigational drug study within 30 days of enrollment or previous participation in this study.
- •Employees or family members of employees of the research center or investigator.
研究组 & 干预措施
Diclofenac Sodium Gel 3%
Experimental
Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
干预措施: Diclofenac Sodium Gel 3% (Drug)
Solaraze® (diclofenac sodium) Gel 3%
Active Comparator
Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
干预措施: Solaraze® (diclofenac sodium) Gel 3% (Drug)
Vehicle Topical Gel
Placebo Comparator
Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
干预措施: Vehicle Topical Gel (Drug)
结局指标
主要结局
Bioequivalence
时间窗: Study day 90 (30 days after completion of 60 days of treatment)
Bioequivalence will be determined by evaluating the proportion of patients in the test and reference groups with 100% clearance of all AK lesions in the treatment area.
次要结局
- Superiority to placebo(Study day 90 (30 days after completion of 60 days of treatment))
研究者
相似试验
已完成
1 期
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne VulgarisAcne VulgarisNCT01769664Taro Pharmaceuticals USA650
已完成
1 期
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.Actinic KeratosisNCT01788007Taro Pharmaceuticals USA443
终止
3 期
A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis ExternaOtitis ExternaNCT01910155Par Pharmaceutical, Inc.455
已完成
3 期
Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic ConstipationChronic Idiopathic ConstipationNCT01674530Dr. Reddy's Laboratories Limited909
终止
3 期
Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy TubesOtitis Media in Patients With Tympanostomy TubesNCT01994642Par Pharmaceutical, Inc.203